Bioclinical Parameters Driving Decision-Making of Subsequent Lines of Treatment in Metastatic Castration-Resistant Prostate Cancer

Different options are available as second-line treatment of metastatic castrate-resistant prostate cancer: cabazitaxel, abiraterone, and enzalutamide. Phase III studies evaluating cabazitaxel and the two hormonal agents have been shown to significantly prolong overall survival compared to mitoxantro...

Full description

Saved in:
Bibliographic Details
Main Authors: Irelli, A., Bruera, G., Cannita, K., Palluzzi, E., Gravina, G. L., Festuccia, C., Ficorella, C., Ricevuto, E.
Format: Artigo
Language:Inglês
Published: Hindawi Publishing Corporation 2014
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4058260/
https://ncbi.nlm.nih.gov/pubmed/24971356
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2014/909623
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items